VAX 125

Drug Profile

VAX 125

Alternative Names: Flagellin.HuHA; Hemagglutinin (HA)-based seasonal influenza vaccine - VaxInnate; STF2.HA1 (SI) - VaxInnate; VAX125

Latest Information Update: 27 Aug 2015

Price : $50

At a glance

  • Originator VaxInnate
  • Class Influenza A vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus infections

Most Recent Events

  • 27 Aug 2015 No recent reports on development identified - Phase-II for Influenza-A virus infections (In the elderly) in USA (IM)
  • 19 Dec 2011 VaxInnate's recombinant seasonal and pandemic influenza vaccines licensed to CJ CheilJedang Corporation exclusively in South Korea, and non-exclusively in certain South-East Asia countries, excluding China
  • 25 Jul 2011 VaxInnate completes a phase II trial in Influenza A virus infections (prevention) in patients aged ≥65 years in USA (NCT00966238)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top